Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Appointed director
CC transcript
Auditor change
Vaxart, Inc. (VXRT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: " "
05/09/2023 8-K Quarterly results
Docs: "Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results"
11/08/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: " "
08/05/2021 8-K Quarterly results
Docs: " "
02/25/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Vaxart, Inc. Condensed Consolidated Balance Sheets"
08/06/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
03/19/2020 8-K Quarterly results
Docs: "Vaxart, Inc. Condensed Consolidated Balance Sheets",
"Press release, titled “Vaxart Announces it Entered into an Agreement with Emergent Biosolutions for the Development and Manufacturing of Oral Coronavirus (COVID-19) Vaccine Candidate”"
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "Vaxart, Inc. Condensed Consolidated Balance Sheets Assets Cash and cash equivalents $ 8,424 $ 11,506 Accounts receivable 5,584 1,796 Prepaid and other assets 1,346 1,446 Property and equipment, net 1,559 1,066 Right-of-use assets, net 762 — Intangible assets, net 18,634 19,413 Total assets $ 36,309 $ 35,227 Liabilities and stockholders’ equity Accounts payable $ 849 $ 962 Accrued and other liabilities 1,745 1,675 Liability related to sale of future royalties 16,901 17,741 Secured promissory note 3,229 3,611 Operating lease liabilities 1,009 — Total liabilities 23,733 23,989 Stockholders’ equity 12,576 11,238 Total liabilities and stockholders’ equity $ 36,309 $ 35,227 Derived from the audited consolidated financial statements of Vaxart, Inc. for the year ended December 31, 2018, included ..."
02/06/2019 8-K Quarterly results
11/09/2018 8-K Quarterly results
Docs: "Vaxart Announces Third Quarter 2018 Financial Results and Provides Corporate Update"
08/09/2018 8-K Quarterly results
Docs: "Vaxart Announces Second Quarter 2018 Financial Results and Corporate Update SOUTH SAN FRANCISCO, Calif., August 9, 2018 - Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the second quarter ended June 30, 2018 and provided a corporate update."
05/15/2018 8-K Quarterly results
Docs: "Vaxart Announces First Quarter 2018 Financial Results and Corporate Update SOUTH SAN FRANCISCO, Calif., May 15, 2018 - Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the first quarter ended March 31, 2018 and provided a corporate update. “Since the start of this year, we have made considerable progress advancing our business objectives and progressing our oral vaccine candidates as well as teslexivir ® for the treatment of condyloma caused by HPV,” said Wouter Latour, chief executive officer of Vaxart. “Moreover, with the addition of Dr. David Taylor as our new chief medical officer, we are exceedingly well positioned to execute on the clinical strateg..."
11/02/2017 8-K Quarterly results
Docs: "AVIRAGEN THERAPEUTICS REPORTS FIRST QUARTER OF FISCAL YEAR 2018 FINANCIAL RESULTS"
09/05/2017 8-K Quarterly results
05/04/2017 8-K Form 8-K - Current report
02/03/2017 8-K Form 8-K - Current report
11/03/2016 8-K Quarterly results
Docs: "AVIRAGEN THERAPEUTICS REPORTS FIRST QUARTER FISCAL YEAR 2017 FINANCIAL RESULTS"
05/09/2016 8-K Form 8-K - Current report
02/05/2016 8-K Form 8-K - Current report
11/06/2015 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
09/11/2015 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
05/07/2015 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
02/06/2015 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
11/07/2014 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
09/30/2014 8-K Quarterly results
Docs: "Press release"
05/07/2014 8-K Quarterly results
Docs: "Biota Pharmaceuticals, Inc. ☐ 2500 Northwinds Parkway, Suite 100 ☐ Alpharetta, GA 30009 ☐ Tel: 221-3343 BIOTA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS Current assets Cash and cash equivalents $ 80.1 $ 66.8 Accounts receivable 36.5 11.0 Prepaid and other current assets 0.9 2.2 Total current assets 117.5 80.0 Non-current assets: Property and equipment, net 2.8 3.7 Intangible assets, net 0.2 0.6 Total non-current assets 3.0 4.3 Total assets $ 120.5 $ 84.3 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 7.3 $ 4.4 Accrued expenses 16.1 8.4 Accrued severance obligations 0.9 3.0 Deferred revenue - 0.3 Total current liabilities 24.3 16.1 Non-current liabilities: Other liabilities, net of current portion 0.2 0.2 Total liabili..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy